Gustavo Albizu
General Practice · Morovis, PRNPI 1043265374
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $192 of the $215 with a category attached, or 89.2%. 3 manufacturers reported payments, led by Merck at 57.3% of the total. 2025 is the largest year on record at $123, 4.0 times the $31 reported in 2019.
Across 5 payments — averaging $43.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$123
- Boston Scientific$69
- AstraZeneca$23
Across 134 payments — averaging $23,290 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.6M
- Sanofi Pasteur Inc.$1.5M
- Amgen$28K
What the payments were for
- Food & beverage$19289%
- Education$2311%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $123 |
| Boston Scientific | 3 | $69 |
| AstraZeneca | 1 | $23 |
How this compares
$215 in reported general payments places this provider in the 55th percentile of 3,586 general practice providers in Puerto Rico.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Jentadueto XrLinagliptin/Metformin Hcl | 107 | $65,992 |
| EliquisApixaban | 105 | $63,303 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 80 | $52,910 |
| FarxigaDapagliflozin Propanediol | 70 | $50,999 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 51 | $32,226 |
| JardianceEmpagliflozin | 29 | $27,468 |
| SynthroidLevothyroxine Sodium | 310 | $22,520 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 21 | $20,788 |
| JanumetSitagliptin Phos/Metformin Hcl | 25 | $19,216 |
| JanuviaSitagliptin Phosphate | 24 | $17,359 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $15,721 |
| LantusInsulin Glargine,hum.Rec.Anlog | 126 | $14,399 |
| XareltoRivaroxaban | 16 | $13,600 |
| Xigduo XrDapaglifloz Propaned/Metformin | 15 | $13,463 |
| TradjentaLinagliptin | 17 | $11,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet Xr, Janumet, Januvia | $123 | $89,485129 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $23 | $61,51595 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 3,586 general practice providers in Puerto Rico.
Other general practice in Morovis
- Wilfredo CuevasSan Lorenzo$530K
- Julio BacoMayaguez$268K
- Soria Diaz BaezPonce$192K
- Carlos RomanCanovanas$140K
- William E TorresSan Juan$86K
- Rafael Mendoza RodriguezPonce$77K
- Frank Perez NogueiraSan German$70K
- Vivian Tamayo AgraitSan Juan$64K
- William Soto AvilesToa Baja$63K
- Jessica RosarioSanturce$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.